Bronchogen (Bronchogen (Ala-Asp-Glu-Leu Bronchopulmonary Bioregulator))
A short synthetic peptide bioregulator from the Khavinson family targeted at bronchopulmonary (lung/airway) tissue, closely related to Chonluten. Used in the bioregulator community for respiratory support in short repeated courses.
How it works
As a signal peptide (Ala-Asp-Glu-Leu), it is proposed to regulate gene expression in respiratory epithelial tissue, supporting airway lining integrity, antioxidant defense, and local respiratory immune function.
Key facts
- Molecular weight: ~445 Da
- Half-life: Short (peptide)
- Bioavailability: Oral (encapsulated) or subcutaneous
- Storage: Room temperature (capsules) or refrigerate (injectable).
Dosing overview
- Typical dose: ~1-2 capsules/day or short injectable courses
- Frequency: Once daily
- Duration: 10-30 day courses
- Route: Oral capsule or subcutaneous
Protocol notes
- Taken as short repeatable courses (often 10-30 days), a few times per year.
- Oral encapsulated forms are taken once daily on an empty stomach.
- Often used seasonally for respiratory support.
Reported benefits
- Respiratory/airway support
- Bronchopulmonary tissue maintenance (proposed)
- Local respiratory immune support
- Short course-based protocol
Possible side effects
- Limited Western clinical data
- Injection site reactions (injectable)
- Unknown long-term effects
Research
- Bronchopulmonary peptide bioregulators (2016): Reported to support respiratory epithelial function and antioxidant defense in regional research studies.
Compare Bronchogen
Research and educational reference only. Not medical advice.